共 17 条
[1]
Second-generation sulfony-lureas preserve inhibition of mitochondrial permeability transition bythe mitochondrial K+(ATP)opener nicorandil in experimental myo-cardial infarction. Argaud L,Garrier O,Loufouat J,et al. Shock . 2009
[2]
SECOND-GENERATION SULFONYLUREAS PRESERVE INHIBITION OF MITOCHONDRIAL PERMEABILITY TRANSITION BY THE MITOCHONDRIAL KATP+ OPENER NICORANDIL IN EXPERIMENTAL MYOCARDIAL INFARCTION
[J].
SHOCK,
2009, 32 (03)
:247-252
Argaud, Laurent
;
Garrier, Olivier
;
Loufouat, Joseph
;
Gomez, Ludovic
;
Couture-Lepetit, Elisabeth
;
Gateau-Roesch, Odile
;
Robert, Dominique
;
Ovize, Michel
.
[3]
Selective cardiac plasma-mem-brane K (ATP)channel inhibition is defibrillatory and improves survivalduring acute myocardial ischemia and reperfusion. Vajda S,BaczkóI,Leprán I. European Journal of Pharmacology . 2007
[4]
Increase in overall mor-tality risk in patients with type 2 diabetes receiving glipizide,glyburideor glimepiride monotherapy versus metformin:a retrospective analysis. Pantalone KM,Kattan MW,Yu C,et al. Diabetes Obesity and Metabolism . 2012
[5]
Hypoglyce-mia in hospitalized patients treated with sulfonylureas. Deusenberry CM,Coley KC,Korytkowski MT,et al. Pharmacotherapy . 2012
[6]
Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular Outcomes in Diabetic Patients with Acute Myocardial Infarction
[J].
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM,
2010, 95 (11)
:4993-5002
Zeller, Marianne
;
Danchin, Nicolas
;
Simon, Dominique
;
Vahanian, Alec
;
Lorgis, Luc
;
Cottin, Yves
;
Berland, Jacques
;
Gueret, Pascal
;
Wyart, Pascal
;
Deturck, Regis
;
Tabone, Xavier
;
Machecourt, Jacques
;
Leclercq, Florence
;
Drouet, Elodie
;
Mulak, Genevieve
;
Bataille, Vincent
;
Cambou, Jean-Pierre
;
Ferrieres, Jean
;
Simon, Tabassome
.
[7]
The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats. K Pompermayer,DG Souza,GG Lara,KD Silveira,GD Cassali,AA Andrade. Kidney International . 2005
[8]
10-year follow-up of intensive glucose control in type 2 diabetes. Holman RR,Paul SK,Bethel MA et,al. The New England Journal of Medicine . 2008
[9]
The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. KM Pantalone,MW Kattan,C Yu,BJ Wells,S Arrigain,A Jain,A Atreja,RS Zimmerman. Diabetes Care . 2010
[10]
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Mellbin LG,Malmberg K,Norhammar A,Wedel H,Ryden L. European Heart Journal . 2008